Ionis Pharmaceuticals Stock Upgraded (IONS): Company on Path to Profitability?

Ionis Pharmaceuticals stock (NASDAQ: IONS) is trading higher this morning, up 2.18% in the pre-market. Confidence is growing, with analysts projecting a clearer path to profitability ahead.

The recent optimism stems from multiple factors, prominently including an upgrade from JPMorgan analyst Jessica Fye. Fye raised Ionis from “Neutral” to “Overweight,” setting a new price target of $80, significantly up from the previous $49.

The rationale behind this upgrade centers on Ionis’s multiple product launches and their potential to drive the company toward breakeven. The analyst’s positive outlook is further fueled by the promising acute pancreatitis benefit observed with olezarsen, leading to raised estimates for the drug.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

JPMorgan also factored in risk-adjusted credit for ION582 and zilganersen, anticipating continued share outperformance.

HC Wainwright also raised its price target for Ionis in August, from $70 to $95, maintaining a “Buy” rating, reflecting optimism about the company’s pipeline and recent clinical successes.

Encouraging Clinical Trial Results

Adding to the positive sentiment, Ionis has reported encouraging clinical trial results for key pipeline candidates. Zilganersen, aimed at treating Alexander Disease, met its primary endpoint in a pivotal study, demonstrating a disease-modifying impact.

Specifically, the drug showed statistical significance in improving gait speed, as measured by the 10-Meter Walk Test at week 61 compared to the control group. Similarly, olezarsen has shown positive results in treating severe Hypertriglyceridemia (sHTG), with notable benefits in addressing acute pancreatitis.

Ionis’s stock performance has reflected these positive developments, up 98.73% YTD, showing a substantial upswing in investor confidence.

The series of analyst upgrades, positive clinical trial results, and subsequent market performance underscore Ionis Pharmaceuticals’ advancements in its clinical pipeline and strategic initiatives toward profitability. The company appears to be entering a new phase marked by a clearer path to financial sustainability. These factors collectively contribute to a more favorable outlook among analysts and the market.